• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

PAD4-Induced NETosis Via Cathepsin G-Mediated Platelet-Neutrophil Interaction in ChAdOx1 Vaccine-Induced Thrombosis
CONCLUSIONS: Patients with VITT display enhanced thrombogenesis by PAD4-mediated NETs formation via cathepsin G-mediated platelet/neutrophil interaction.PMID:37586040 | DOI:10.1161/ATVBAHA.123.319522
Source: Arteriosclerosis, Thrombosis and Vascular Biology - August 16, 2023 Category: Cardiology Authors: Roberto Carnevale Martina Leopizzi Marcello Dominici Giulia d'Amati Simona Bartimoccia Cristina Nocella Vittoria Cammisotto Alessandra D'Amico Valentina Castellani Francesco Baratta Alessia Bertelli Alessio Arrivi Danilo Toni Manuela De Michele Pasquale P Source Type: research

Thrombocytopenia Following Perceval Sutureless Aortic Valve Replacement in Asian Patients
CONCLUSIONS: Thrombocytopenia was common after Perceval sutureless AVR, although its impact was not significant. Although Perceval sutureless AVR was found to be a safe and effective option, preoperative assessment of potential bleeding should be performed and the Perceval valve should not be used for patients with a high bleeding risk.PMID:36709983 | DOI:10.1253/circj.CJ-22-0587
Source: Circulation Journal - January 29, 2023 Category: Cardiology Authors: Taisuke Nakayama Yoshitsugu Nakamura Fumiaki Shikata Masaki Ushijima Yuto Yasumoto Daiki Yoshiyama Miho Kuroda Shintaro Sawa Ryo Tsuruta Akira Furutachi Takuya Narita Yujiro Ito Source Type: research

Combined use of the GRACE ACS risk score and comorbidity indices to increase the effectiveness of hospital mortality risk assessment in patients with acute coronary syndrome
CONCLUSION: CCI and its own comorbidity model, but not CDS and CIRS, are associated with the risk of hospital mortality. The model for assessing comorbidity on a 9-point scale, but not CCI, CDS and CIRS, can significantly improve the predictive value of the GRACE scale.PMID:36286937 | DOI:10.26442/00403660.2022.07.201742
Source: Atherosclerosis - October 26, 2022 Category: Cardiology Authors: M V Zykov N V Dyachenko R M Velieva V V Kashtalap O L Barbarash Source Type: research

Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination
Circ Res. 2022 Apr 15;130(8):1187-1203. doi: 10.1161/CIRCRESAHA.122.319954. Epub 2022 Apr 14.ABSTRACTThe risk of stroke and cerebrovascular disease complicating infection with SARS-CoV-2 has been extensively reported since the onset of the pandemic. The striking efforts of many scientists in cooperation with regulators and governments worldwide have rapidly brought the development of a large landscape of vaccines against SARS-CoV-2. The novel DNA and mRNA vaccines have offered great flexibility in terms of antigen production and led to an unprecedented rapidity in effective and safe vaccine production. However, as mass vac...
Source: Circulation Research - April 14, 2022 Category: Cardiology Authors: Manuela De Michele Joshua Kahan Irene Berto Oscar G Schiavo Marta Iacobucci Danilo Toni Alexander E Merkler Source Type: research

Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation
ConclusionsPercutaneous LAAC in primary HD carriers appeared as safe and as effective as in overall LAAC population for stroke and bleeding prevention at midterm follow-up.Graphical abstractPercutaneous left atrial appendage closure in patients with atrial fibrillation and primary hemostasis disorders. The percutaneous LAAC in primary hemostasis disorders and AF carriers requires a multidisciplinary approach. Cardiologist, anesthesiologist, and hematologist discussion is a cornerstone to assess anticoagulant contraindication, LAAC feasibility, periprocedural management, and follow-up(high). This multidisciplinary care is i...
Source: Journal of Interventional Cardiac Electrophysiology - November 25, 2021 Category: Cardiology Source Type: research

A case series analysis on the clinical experience of Impella 5.5 ® at a large tertiary care centre
ConclusionsIn this early experience of the pVAD 5.5, procedural and device-related complications were observed but were manageable, and overall survival was high in this critically ill cohort, particularly when the device was used as a bridge to other therapies.
Source: ESC Heart Failure - August 17, 2021 Category: Cardiology Authors: Peter J. Kennel, Heidi Lumish, Yuji Kaku, Justin Fried, Ajay J. Kirtane, Dimitri Karmpaliotis, Hiroo Takayama, Yoshifumi Naka, Gabriel Sayer, Nir Uriel, Koji Takeda, Amirali Masoumi Tags: Original Research Article Source Type: research

Percutaneous Right Ventricular Assist Device Using the TandemHeart ProtekDuo: Real-World Experience
CONCLUSIONS: This real-world experience, despite high morbidity, continues to suggest benefits of THPD for patients with severe acute RV failure.PMID:33771937
Source: The Journal of Invasive Cardiology - March 27, 2021 Category: Cardiology Authors: Estefania Oliveros Fareed M Collado Marie F Poulin Christopher W Seder Robert March Clifford J Kavinsky Source Type: research

Pages: 1  2  3